Sign in Subscribe
Securities law

Securities Class Action Filed Against Alto Neuroscience, Inc.

Strategic Insights

— 2 min read

Investors who purchased or acquired Alto common stock in the initial public offering conducted on or about February 2, 2024, or between February 2, 2024, and October 22, 2024, may have incurred significant losses due to allegedly false and misleading statements made by the company. A federal securities class action has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company"), alleging that the company and its executives violated federal securities laws. Investors who suffered losses exceeding $50,000 are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly to discuss their options.

Key Takeaways:

  • The complaint alleges that Alto and its executives made false and/or misleading statements about the efficacy of ALTO-100, a treatment for Major Depressive Disorder (MDD), and the company's clinical, regulatory, and commercial prospects.
  • The complaint claims that ALTO-100's Phase 2b trial results, announced on October 22, 2024, showed that the treatment did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
  • As a result of the defective treatment claims, Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • The company's executives and directors, including CEO Glenn A. O'Donnell, are accused of breaching their fiduciary duties and making reckless and/or intentional misstatements to investors.
  • Analysts, such as Jeffries, have commented on the company's announcement, expressing concerns about the treatment's efficacy and the company's overall biomarker approach to CNS disorders and psychiatry.
  • Faruqi & Faruqi encourages anyone with information regarding Alto's conduct to contact the firm, including whistleblowers, former employees, and shareholders.

Statistics:

  • The initial public offering (IPO) of Alto common stock was conducted on or about February 2, 2024.
  • The alleged class period spans from February 2, 2024, to October 22, 2024.
  • On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial.
  • ALTO-100's stock price fell by 69.99% to close at $4.36 per share on October 23, 2024.
  • On October 22, 2024, Jeffries cut its price target for Alto to $17 from $33, stating that ALTO-100's data raises questions around the company's overall biomarker approach to CNS disorders and psychiatry.

Sources:

  • Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
  • Newsfile Corp. - September 14, 2025 - Faruqi & Faruqi, LLP Investigating Potential Claims Against Alto Neuroscience, Inc.

Read more